Buy Like Buffett
Watchlist

Niagen Bioscience, Inc.

NAGE · Healthcare · $256M mkt cap · FY2025 filings · Narrow moat ·

On the watchlist

Narrow moat
Share / Embed this score
Embed this score

The five investor questions

85

2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $67.4M to $129M, increasing; diluted EPS -0.40 to 0.20, increasing.

91

Median gross margin 59.5% over 10y, stable.

8

Median ROIC -175.8%, above the 12% hurdle in 22% of years.

100

Net cash position — no leverage risk.

24

Owner earnings changed trend unclear over up to the ten most recent annual observations.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today
No price data
Not reported
Unavailable — insufficient owner-earnings data
Unavailable — insufficient growth-model data
$3.21
No price data

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.

Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.

Score records captured Jul 26, 2026.

Exactly which 50 companies?

FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY

Missing a usable price or zero-growth estimate: ANF, BKNG.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

17 years of fundamentals

The business, in plain English

Niagen Bioscience, Inc. booked $129M of revenue in FY2025 in the Healthcare sector and kept 64.3% of it as gross profit — a high-margin business by that measure. After every other cost, 13.4% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $7.6M (FY2010) to $129M (FY2025) — about 20.8% a year compounded over 15 years.

It earned 132.4% on invested capital in the latest filed year, FY2025. Across the full 15-year measurable filed record, median ROIC was −66.7%. Over the v3 recent window (9 measurable filed years), median ROIC was −175.8%. The Returns on Capital filter above scores it 8/100.

NAGE's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.

Put together: Balance-Sheet Safety is the strongest of the five filters (100/100) and Returns on Capital the weakest (8/100), which is how NAGE lands at 62/100 — a Narrow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2009–FY2025 · 17 fiscal years, normalized from NAGE’s SEC filings

Sales, as filed$129M FY2025
$0$50M$100M2009201520212025
Revenue kept after cost of goods64.3% FY2025
0%25%50%2009201520212025
Standard ROIC or separately labeled Operating ROICROIC 132.4% FY2025
−1000%0%2009201520212025
Cash an owner could take out$17.4M FY2025
−$20M$0$20M2009201520212025

Gaps in a line mean that item isn’t in NAGE’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Flagship explainer

How Niagen Bioscience, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$129M · 100%Cost of revenue$46.2M · 36%Gross profit$83.2M · 64%Operating income$16.3M · 13%Income before tax$18.2M · 14%Income tax$810000 · 1%Net income$17.4M · 13%As of 2025-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$129M100%
Cost of revenue$46.2M36%
$83.2M64%
$16.3M13%
Income before tax$18.2M14%
Income tax$8100001%
$17.4M13%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

Flagship explainer

What Niagen Bioscience, Inc. owns — and owes

Niagen Bioscience, Inc.'s filing tags don't support a full breakdown — here's what is filed:

Table alternative
Filed lineValue% of assetsSource
Total assets$106M100%
Cash and equivalents$64.8M61%
Stockholders’ equity$76.5M72%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Flagship explainer

What drives Niagen Bioscience, Inc.’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity28%Tax burden96%net income ÷ pretax incomeInterest burden112%pretax ÷ operating incomeOperating margin13%operating income ÷ revenueAsset turnover1.48×revenue ÷ average assetsEquity multiplier1.42×average assets ÷ average equityAs of 2025-12-31 · 3 SEC filing sourcesBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
$17.4MFY2025
Income before tax$18.2MFY2025
Operating income$16.3MFY2025
$129MFY2025
Ending assets$106MFY2025
Beginning assets$68.3MFY2024
$76.5MFY2025
$46.1MFY2024
Source:
  • SEC filingFiling detailsAccession 0001386570-26-000013
  • SEC filingFiling detailsAccession 0001628280-25-009774
· event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

Flagship explainer

Where Niagen Bioscience, Inc.'s cash went

Niagen Bioscience, Inc.’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:

Table alternative
Filed lineValue% of cash from operationsSource
Cash from operations$13.5M100%
Depreciation and amortization$7850006%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Curated 19-manager tier

Who reported holding Niagen Bioscience, Inc.

Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.

0 holding0 exited0 not holding0/19 resolved19 unavailable

Named manager positions and quarter-over-quarter changes
ManagerReported positionQuarter-over-quarterFiling accession
Abrams CapitalUnavailableComparison unavailableFiling unavailable
Akre CapitalUnavailableComparison unavailableFiling unavailable
Baupost GroupUnavailableComparison unavailableFiling unavailable
Berkshire HathawayUnavailableComparison unavailableFiling unavailable
Brave Warrior AdvisorsUnavailableComparison unavailableFiling unavailable
Dodge & CoxUnavailableComparison unavailableFiling unavailable
First EagleUnavailableComparison unavailableFiling unavailable
FundsmithUnavailableComparison unavailableFiling unavailable
Gardner Russo & QuinnUnavailableComparison unavailableFiling unavailable
Gates Foundation TrustUnavailableComparison unavailableFiling unavailable
Mairs & PowerUnavailableComparison unavailableFiling unavailable
Markel / Markel-GaynerUnavailableComparison unavailableFiling unavailable
Oakmark / Harris AssociatesUnavailableComparison unavailableFiling unavailable
Pershing SquareUnavailableComparison unavailableFiling unavailable
Polen CapitalUnavailableComparison unavailableFiling unavailable
Sequoia / Ruane CunniffUnavailableComparison unavailableFiling unavailable
Southeastern Asset ManagementUnavailableComparison unavailableFiling unavailable
Tweedy, BrowneUnavailableComparison unavailableFiling unavailable
Yacktman Asset ManagementUnavailableComparison unavailableFiling unavailable

Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.

Source: Filing source unavailable · event Jun 30, 2026 · retrieved Jul 26, 2026

Flagship explainer

What Niagen Bioscience, Inc. insiders reported

Records still being gathered — partial as of retrieval Aug 18, 2026.

Partial coverage: the incomplete Form 4 walk cannot establish no activity, an activity date, or zero counts.

Moat Score history

15 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale61.6 / 100
0406080100WideNarrowShallowNo moatJul 17, 2026Jul 26, 2026

Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

  1. Normalizer upgraded unstamped (version unknown)moat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
  2. Methodology upgraded moat-index@2.0.0moat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
  3. Methodology upgraded moat-index@1.2.0moat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.

Records still being gathered — partial as of retrieval Aug 18, 2026.

Trailing-12-month totals and the 90-day cluster result are withheld because this issuer walk is incomplete.

No reported Form 4 rows were captured for NAGE; the incomplete walk cannot establish zero activity, zero counts, or a negative cluster result.

A filing source-event date will appear when a Form 4 row is captured.

Retrieved .

Healthcare context

#99 of 710 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #97DCTH DELCATH SYSTEMS, INC.61.7Narrow moat
  2. #98NVAX NOVAVAX, INC.61.6Narrow moat
  3. #100CDRE CADRE HOLDINGS, INC.61.4Narrow moat
  4. #101BIOE BIO ESSENCE CORP.61.2Narrow moat

Compare NAGE with its nearest peers →All Healthcare companies on the Index →

Common questions about NAGE

Does Niagen Bioscience, Inc. have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores Niagen Bioscience, Inc. (NAGE) 61.6 out of 100 — a Narrow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 85, pricing power 91, returns on capital 8, balance-sheet safety 100, capital allocation 24.
How has NAGE's Moat Score changed over time?
The record logs 15 readings since Jul 17, 2026; the latest reads 61.6 out of 100 (narrow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell NAGE. See the disclaimer.